文献速递免疫规划传染病防控与疫情报告

冻干纯化人二倍体细胞狂犬病疫苗按Essen和Zagreb狂犬病暴露后预防方案接种的安全性、免疫原性和免疫持久性:一项在10-60岁健康参与者中开展的随机盲法对照3期试验

Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.
PubMed 文献 · Vaccine · 2025-04-05

研究将1800名10-60岁健康未接种者按1:1:1随机分为5剂试验组(T5,Essen方案)、5剂对照组(C5,Essen方案)和4剂试验组(T4,Zagreb方案),评估冻干纯化人二倍体细胞狂犬病疫苗模拟暴露后预防的安全性、免疫原性和免疫持久性。结果显示试验疫苗在两种方案下安全性、免疫原性和免疫持久性良好,不劣于对照疫苗。

要点

  • T4总不良事件发生率38%低于C5的45%(P=0.02),T5发热率12%(P=0.01)和T4发热率13%(P=0.03)低于C5的17%。
  • 三组首剂后14天血清阳转率均达100%,首剂后12个月T5、C5、T4分别为98%、96%、98%。
  • T5和T4在首剂后7天、14天、12个月及末剂后14天的中和抗体GMC和GMI高于C5,T5与T4间无显著差异。

核心结论

  • 试验疫苗按Essen方案和Zagreb方案接种均显示出良好的安全性、免疫原性和免疫持久性,且不劣于对照疫苗。

研究设计与样本

  • 随机、盲法对照3期试验,纳入1800名10-60岁健康且既往未接种狂犬病疫苗的参与者,按1:1:1随机分为5剂试验组(T5,Essen方案)、5剂对照组(C5,Essen方案)和4剂试验组(T4,Zagreb方案)。

主要发现

  • 不良事件主要发生在首剂免疫后,严重程度多为轻度(1级)。
  • 从首剂至末剂后28天,T4总不良事件发生率为38%,低于C5的45%(P=0.02)。
  • 发热率T5为12%(P=0.01)、T4为13%(P=0.03),均低于C5的17%。
  • 未观察到疫苗相关严重不良事件(SAEs)。
  • 首剂后14天三组血清阳转率均达100%;首剂后12个月T5、C5、T4血清阳转率分别为98%、96%、98%。

关键数值与推荐

  • T5和T4在首剂后7天、14天、12个月及末剂后14天的中和抗体几何平均浓度(GMC)和几何平均增长倍数(GMI)均高于C5;T5与T4在不良事件发生率、血清阳转率、GMC和GMI方面无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine in healthy and previously unvaccinated people in a simulated rabies post-exposure prophylaxis, by traditional 5-dose Essen regimen and abbreviated 4-dose Zagreb regimen. METHODS: A cohort of 1800 healthy participants aged 10-60 years old were randomized into three groups: 5-dose test group (T5, Essen regimen), 5-dose control group (C5, Essen regimen) and 4-dose test group (T4, Zagreb regimen) according to the ratio of 1:1:1, and inoculated with trial vaccine or control vaccine separately to analyze the safety of vaccine as well as rabies antibody levels before and after vaccination. RESULTS: Adverse reactions (AEs) mainly occurred after the initial dose of immunization, which were mostly mild (grade 1) in severity. The incidence of total AEs in T4 (38 %) was lower than that in C5 (45 %) (P = 0.02) from the initial dose to 28 days after the final dose; fever rate in T5 (12 %, P = 0.01) and T4 (13 %, P = 0.03) was lower than that in C5 (17 %). No vaccine-related serious AEs (SAEs) were observed. Seroconversion rates reached 100 % in all three groups 14 days following the first dose. Moreover, the seroconversion rate was 98 %, 96 % and 98 % 12 months following the first dose in T5, C5 and T4, respectively. Both T5 and T4 displayed higher neutralizing antibodies geometric mean concentration (GMC) and geometric mean increase (GMI) compared to those in C5 on day 7, day 14, and 12 months after the first dose, as well as on day 14 after the last dose. There were no significant differences in the incidence of AEs, seroconversion rate, GMC and GMI between T5 and T4. CONCLUSION: The trial vaccine administered following both Essen regimen and Zagreb regimen shows good safety, immunogenicity and immune persistence, and the trial vaccine is not inferior to the control vaccine. CLINICAL TRIALS REGISTRATION: NCT03971370.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li G, Cao S, Xu B, et al. Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old. Vaccine. 2025. PMID: 40188565. doi:10.1016/j.vaccine.2025.127082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。